Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of rituximab and intrathecal DepoCyte added to the C5R chemotherapy regimen in primary CNS or neuro-meningeal diffuse large B-cell lymphoma
2006-000454-44Phase 2Completed
- Sponsor
- Groupe d'Étude des Lymphomes de l'Adulte
- Start
- Apr 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab and liposomal cytarabine in primary central nervous system lymphoma (PCNSL) and diffuse large B-cell lymphoma (DLBCL), sponsored by Groupe d'Étude des Lymphomes de l'Adulte. Primary endpoints: Complete response rate after immunochemotherapy and Protocol toxicity. Started Apr 2007; status: completed.
02
Drugs
rituximabliposomal cytarabine
03
Conditions
primary central nervous system lymphoma (PCNSL)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2006-000454-44.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-000454-44.